NDA 022181 · Biomarin Pharm
Kuvan
Sapropterin Dihydrochloride · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Aug 26, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Dec 13, 2007
Approved uses
4
Original approval plus efficacy supplements
Registered trials
64
12 Phase 3, 4 recruiting
FAERS reports
5,907
1,042 serious, 72 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 26, 2024.
KUVAN ® is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin- (BH4-) responsive Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe-restricted diet. KUVAN is a phenylalanine hydroxylase activator indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin‑ (BH4‑) responsive Phenylketonuria (PKU). KUVAN is to be used in conjunction with a Phe‑restricted diet. ( 1 )
Mechanism: KUVAN is a synthetic form of BH4, the cofactor for the enzyme phenylalanine hydroxylase (PAH). PAH hydroxylates Phe through an oxidative reaction to form tyrosine. In patients with PKU, PAH activity is absent or deficient. Treatment with BH4 can activate residual PAH enzyme activity, improve the normal oxidative metabolism of Phe, and decrease Phe levels in some patients.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 23, 2014 Supplement 13 · Efficacy · priority review OrphanLabelPediatric Medical ReviewPediatric Clinical Pharmacology Review
- Dec 19, 2013 Supplement 10 · Efficacy LabelLetter
- Dec 19, 2013 Supplement 9 · Efficacy LabelLetter
- Dec 13, 2007 Original approval · Type 1 - New Molecular Entity · priority review NovelReviewQuestions and AnswersLabel
1 products under this application
- KUVAN · SAPROPTERIN DIHYDROCHLORIDE 100MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sapropterin Dihydrochloride" as an intervention, any sponsor and status, largest first.
BioMarin PharmaceuticalBioMarin (BMRN)
NCT00104260 · 700 participants · Start Dec 2004
Drug: sapropterin dihydrochloride · For: Phenylketonurias
Sites: Los Angeles, California; Oakland, California; New Haven, Connecticut · 13 sites in all
- A Study for Assessing the Efficacy and Safety of BH4 in Radiation EnteritisPivotal-lookingStatus unknown
West China Second University HospitalAcademic, hospital or other
NCT05138887 · 366 participants (planned) · Start Mar 1, 2022 · Primary completion Oct 1, 2023
Drug: Tetrahydrobiopterin · For: Radiation Enteritis
Sites: Chengdu, China
- Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) PatientsPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT01114737 · 206 participants · Start Aug 2010 · Primary completion Mar 2013
Drug: Sapropterin dihydrochloride; Placebo · For: Phenylketonuria
Sites: La Jolla, California; Los Angeles, California; Palo Alto, California · 36 sites in all
- A Phase 2 Study of the Effects of Sapropterin Dihydrochloride on Symptomatic Peripheral Arterial DiseasePivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT00403494 · 190 participants · Start Dec 2006 · Primary completion Nov 2008
Drug: Sapropterin Dihydrochloride · For: Intermittent Claudication
Sites: Scottsdale, Arizona; Sacramento, California; San Diego, California · 20 sites in all
- Neurovascular Transduction During Exercise in Chronic Kidney DiseasePivotal-lookingRecruiting
Emory UniversityAcademic, hospital or other
NCT02947750 · 150 participants (planned) · Start Oct 2016 · Primary completion Apr 30, 2027
Drug: 6R-BH4 · For: Renal Insufficiency, Chronic
Sites: Atlanta, Georgia; Decatur, Georgia · 3 sites in all
- Study of Phenoptin in Subjects With Phenylketonuria Who Participated in Protocols PKU-004 or PKU-006Pivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT00332189 · 111 participants · Start Jul 2006 · Primary completion Aug 2009
Drug: sapropterin dihydrochloride · For: Phenylketonuria
Sites: Los Angeles, California; Sacramento, California; San Jose, California · 14 sites in all
- Sex Hormones and Atherosclerosis Prevention in Perimenopausal WomenPivotal-lookingCompleted
University of Colorado, DenverAcademic, hospital or other
NCT02042196 · 100 participants (planned) · Start Dec 2013 · Primary completion May 2, 2016
Drug: KUVAN; Placebo and 3 more · For: Menopause; Aging
Sites: Aurora, Colorado
- A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine LevelsPivotal-lookingCompleted
BioMarin PharmaceuticalBioMarin (BMRN)
NCT00225615 · 100 participants · Start Nov 2005
Drug: sapropterin dihydrochloride · For: Phenylketonurias
Sites: Los Angeles, California; Oakland, California; Sacramento, California · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective358
- headache358
- therapy non-responder356
- vomiting291
- maternal exposure during pregnancy281
- diarrhoea269
- nausea218
- amino acid level increased209
- abdominal pain upper198
- anxiety184
- abdominal discomfort166
- cough150
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 31 |
| 2009 | 99 |
| 2010 | 194 |
| 2011 | 66 |
| 2012 | 57 |
| 2013 | 50 |
| 2014 | 356 |
| 2015 | 387 |
| 2016 | 459 |
| 2017 | 564 |
| 2018 | 521 |
| 2019 | 726 |
| 2020 | 583 |
| 2021 | 550 |
| 2022 | 340 |
| 2023 | 332 |
| 2024 | 308 |
| 2025 | 175 |
| 2026 | 109 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Kuvan (Sapropterin Dihydrochloride)
2024 spending
$3.5M
Beneficiaries
27
229 claims
Per beneficiary
$128,183
$126.92 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $30,637,508 |
| 2021 | $19,517,146 |
| 2022 | $10,325,178 |
| 2023 | $6,802,220 |
| 2024 | $3,460,935 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adjunctive sapropterin dihydrochloride treatment in schizophrenia: A positive proof-of-concept, rater-blind, randomized, multivitamin-controlled study.
Clelland CL, Kantrowitz JT, Choo T, et al. · Schizophr Res 2020 · Letter, Randomized Controlled Trial
- Sapropterin dihydrochloride for phenylketonuria.
Somaraju UR, Merrin M · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Sapropterin dihydrochloride for phenylketonuria.
Somaraju UR, Merrin M · Cochrane Database Syst Rev 2012 · Meta-Analysis, Systematic Review
- Response to sapropterin hydrochloride (Kuvan®) in children with phenylketonuria (PKU): a clinical trial.
Eshraghi P, Noroozi Asl S, Bagheri S, et al. · J Pediatr Endocrinol Metab 2019 · Clinical Trial, Phase II
- Sapropterin dihydrochloride for phenylketonuria.
Somaraju UR, Merrin M · Cochrane Database Syst Rev 2010 · Systematic Review
- Italian national consensus statement on management and pharmacological treatment of phenylketonuria.
Burlina A, Biasucci G, Carbone MT, et al. · Orphanet J Rare Dis 2021 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: BioMarin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.